MFA-022

N/A

Report date: 2025/01/26 17:09:51

Base Information

Drug NameMFA-022

Drug Alias Nameneokine-tethered immunotherapeutic fusion antibody (MediMabBio)Treg modulator (MediMabbio)immune checkpoint inhibitor (Medimabbio)MFA-022

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsRegulatory T-lymphocytes inhibitors

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMediMabBio Inc

China Registration ClassN/A

Develop Information

Active CompaniesMediMabBio Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A